249 related articles for article (PubMed ID: 24815720)
1. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.
Yoo JY; Hurwitz BS; Bolyard C; Yu JG; Zhang J; Selvendiran K; Rath KS; He S; Bailey Z; Eaves D; Cripe TP; Parris DS; Caligiuri MA; Yu J; Old M; Kaur B
Clin Cancer Res; 2014 Jul; 20(14):3787-98. PubMed ID: 24815720
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
5. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
6. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
[TBL] [Abstract][Full Text] [Related]
7. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
[TBL] [Abstract][Full Text] [Related]
8. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.
Li K; Hu C; Xing F; Gao M; Liang J; Xiao X; Cai J; Tan Y; Hu J; Zhu W; Yin W; Li Y; Chen W; Lu B; Mai J; Qiu P; Su X; Yan G; Zhang H; Lin Y
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263275
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.
Bolyard C; Yoo JY; Wang PY; Saini U; Rath KS; Cripe TP; Zhang J; Selvendiran K; Kaur B
Clin Cancer Res; 2014 Dec; 20(24):6479-94. PubMed ID: 25294909
[TBL] [Abstract][Full Text] [Related]
11. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
12. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
19. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
